Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | PRKCH | P24723 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934195 | 0.87 | PRKD3 (0.32) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL21728820 | 0.84 | PDK1 (0.34) | ALDH1A1PDK1 | |
| SCHEMBL6933961 | 0.84 | PDK1 (0.34) | ALDH1A1PDK1 | |
| SCHEMBL12567010 | 0.82 | — | — | |
| SCHEMBL6933338 | 0.79 | FUCA1 (0.39) | ALDH1A1 | |
| SCHEMBL6933742 | 0.79 | — | — | |
| SCHEMBL24270550 | 0.79 | SLC5A2 (0.32) | — | |
| SCHEMBL19997414 | 0.79 | SLC5A2 (0.32) | — | |
| SCHEMBL6933346 | 0.79 | SLC5A2 (0.32) | — | |
| SCHEMBL23226254 | 0.79 | SLC5A2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| US-7811998-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | UNIVERSITY OF KANSAS (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | UNIVERSITY OF KANSAS (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | UNIVERSITY OF KANSAS (US) | 2010-02-25 | — | — | US | disclosed |
| US-7622451-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2009-11-24 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | SSB, IAPP, NLN | ALDH1A1 4309/4885PRKD3 2132/4885PRKCG 2841/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | ALDH1A1 3407/4885PRKD3 2190/4885PRKCG 2839/4885 |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | SSB, IAPP, NLN | ALDH1A1 4309/4885PRKD3 2132/4885PRKCG 2841/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | ALDH1A1 3066/4885PRKD3 1729/4885PRKCG 2391/4885 |
| US-20090187014-A1 | Novobiocin Analogues | SSB, SSBP1, BTD | ALDH1A1 4519/4885PRKD3 2697/4885PRKCG 2634/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | ALDH1A1 4382/4885PRKD3 63/4885PRKCG 246/4885 |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | HSP90B1, HSP90AB2P, HSP90AB1 | ALDH1A1 2718/4885PRKD3 1694/4885PRKCG 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.